Latest Conference Articles

A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.

Iltefat Hamzavi, MD, outlines how symptom questionnaires, comorbidity screening, wound care, and procedures shape hidradenitis suppurativa care.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

New ARCADIA and OLYMPIA LTE data show nemolizumab sustained skin clearance and itch relief for up to 3 years in atopic dermatitis and prurigo nodularis.

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

Iltefat Hamzavi, MD, explains how topical and oral JAK inhibitors fit into vitiligo care and which patients are the best candidates for each approach.

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Linda Stein Gold, MD, discusses LATITUDE Atlas data showing zasocitinib achieved higher PASI 100 rates than deucravacitinib in psoriasis.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Iltefat H. Hamzavi, MD, explains why vitiligo responds slowly, why stabilization matters, and what Tranquillo data mean for future treatment.

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.